Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 7/20 | 0.57 |
| ▸ | PPARA | Q07869 | 7/20 | 0.57 |
| ▸ | PPARG | P37231 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640485 | 0.88 | ALDH1A1 (0.54) | PPARDPPARAPPARGHSD17B10KDM4E | |
| SCHEMBL8884503 | 0.88 | KEAP1 (0.62) | PPARDPPARAPPARGHSD17B10KDM4E | |
| SCHEMBL5443958 | 0.87 | MTNR1A (0.48) | PPARDPPARAPPARGHSD17B10KDM4E | |
| SCHEMBL1471065 | 0.85 | MTNR1A (0.46) | PPARDPPARAPPARGHSD17B10KDM4E | |
| SCHEMBL6839987 | 0.81 | CYP2A6 (0.53) | PPARDPPARAPPARGHSD17B10KDM4E | |
| SCHEMBL14564404 | 0.80 | KEAP1 (0.55) | PPARDPPARAPPARGKEAP1NFE2L2 | |
| SCHEMBL19179568 | 0.80 | PPARD (0.60) | PPARDPPARAPPARGHSD17B10KEAP1 | |
| SCHEMBL15211492 | 0.78 | PPARD (0.55) | PPARDPPARAPPARGKEAP1NFE2L2 | |
| SCHEMBL15211307 | 0.78 | PPARD (0.55) | PPARDPPARAPPARGHSD17B10KEAP1 | |
| SCHEMBL15057380 | 0.78 | KEAP1 (0.56) | PPARDPPARAPPARGLCKKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113825398-A | Pyridazinone compounds and herbicides | 日产化学株式会社 | 2021-12-21 | — | — | CN | disclosed |
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | disclosed |
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | disclosed |
| EP-2079467-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-11-18 | — | — | EP | disclosed |
| US-7759493-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-04-29 | — | — | US | disclosed |
| US-20090312303-A1 | Antidiabetic Bicyclic Compounds | MERCK & CO., INC. (US) | 2009-12-17 | — | — | US | disclosed |
| EP-1846379-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO INC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2079467-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck & Co., Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008054675-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1846379-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck & Co., Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006083781-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, FFAR2, GPR65 | PPARD 19/4885PPARA 23/4885PPARG 7/4885 |
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | GPR119, GLP1R, INSR | PPARD 49/4885PPARA 43/4885PPARG 33/4885 |
| US-20090312303-A1 | Antidiabetic Bicyclic Compounds | GPR119, GPR55, GPR65 | PPARD 15/4885PPARA 27/4885PPARG 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.